Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Seres Therapeutics (MCRB) EBITDA Margin: 2016-2025

Historic EBITDA Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to -6,403.70%.

  • Seres Therapeutics' EBITDA Margin was N/A to -6,403.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -84,328.04%, marking a year-over-year change of. This contributed to the annual value of -90.02% for FY2023, which is 341881.00% up from last year.
  • As of Q3 2025, Seres Therapeutics' EBITDA Margin stood at -6,403.70%, which was down 198.61% from 6,494.01% recorded in Q1 2024.
  • In the past 5 years, Seres Therapeutics' EBITDA Margin ranged from a high of 6,494.01% in Q1 2024 and a low of -64,450.00% during Q4 2023.
  • Its 3-year average for EBITDA Margin is -15,565.25%, with a median of -10,017.94% in 2025.
  • In the last 5 years, Seres Therapeutics' EBITDA Margin slumped by 5,740,487bps in 2023 and then skyrocketed by 2,012,620bps in 2024.
  • Quarterly analysis of 5 years shows Seres Therapeutics' EBITDA Margin stood at -693.42% in 2021, then crashed by 635,171bps to -7,045.13% in 2022, then slumped by 5,740,487bps to -64,450.00% in 2023, then surged by 2,012,620bps to 6,494.01% in 2024, then reached -6,403.70% in 2025.
  • Its EBITDA Margin stands at -6,403.70% for Q3 2025, versus 6,494.01% for Q1 2024 and -64,450.00% for Q4 2023.